Changchun Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changchun Shao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Bin Li
Foresight Therapeutics (Hefei), Co., Ltd , Hefei 230022
1 shared publication- Jia Gao
Department of Oncology, The First Affiliated Hospital & School of Life Sciences, Ministry of Education Key Laboratory for Membrane-less Organelles & Cellular Dynamics, Hefei National Research Center for Interdisciplinary Sciences at the Microscale, Biomedical Sciences and Health Laboratory of Anhui Province, Center for Advanced Interdisciplinary Sciences and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei 230022
1 shared publication - Ke Ruan
The First Affiliated Hospital & School of Life Sciences, Ministry of Education Key Laboratory for Membrane-less Organelles & Cellular Dynamics, Hefei National Research Center for Interdisciplinary Sciences at the Microscale, Biomedical Sciences and Health Laboratory of Anhui Province, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China
1 shared publication - Min Yang
The First Clinical Medical College, Anhui University of Chinese Medicine , Hefei 230022
1 shared publication Sheng Chen
Department of Oncology, The First Affiliated Hospital of Anhui Medical University , Hefei 230022
1 shared publication- Xing Liu
MOE Key Laboratory for Cellular Dynamics, University of Science & Technology of China School of Life Sciences, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 17 (11) , 1021-1034
Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer remains a pressing clinical challenge. Liquid-liquid phase separation has emerged as a new mechanism of drug resistance, yet its role in EGFR-TKI resistance in lung cancer is largely unexplored. Herein, we prioritized Sequestosome 1 (SQSTM1/p62) as a key condensate by integrating proteomics data from EGFR-TKI resistance cell lines and clinical biopsy specimens, in which the cytoplasmic p62 condensate formation positively correlated with EGFR-TKI resistance. Domain mapping demonstrated that the PB1 and UBA domains of p62 were critical for promoting phase separation and reducing sensitivity to EGFR-TKI treatment, whereas S403 phosphorylation promoted p62 condensation and EGFR-TKI resistance. Further xenograft studies validated that reduction of p62 condensation restores EGFR-TKI sensitivity. Kinase enrichment and interaction assays identified TBK1 as an upstream regulator of p62 S403 phosphorylation to promote p62 condensation after pharmacological inhibition of EGFR. Notably, among the five compounds identified from a drug library screen that both disrupted p62 condensate formation and inhibited the viability of resistant cells, the highly selective TBK1 inhibitor GSK8612 stood out. GSK8612 inhibited p62 S403 phosphorylation and consequently, at subcytotoxic doses, synergized with EGFR-TKIs to suppress the viability of resistant cells and tumor growth in the xenograft mouse model. These findings propose TBK1-p62 axis links p62 condensate homeostasis to EGFR-TKI resistance as an underlying mechanism of action and an emerging strategy to resensitize EGFR-TKI treatment in resistant lung cancer.
- 26 June 2026
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 17 (11) , 1021-1034
Open AccessTargeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer remains a pressing clinical challenge. Liquid-liquid phase separation has emerged as a new mechanism of drug resistance, yet its role in EGFR-TKI resistance in lung cancer is largely unexplored. Herein, we prioritized Sequestosome 1 (SQSTM1/p62) as a key condensate by integrating proteomics data from EGFR-TKI resistance cell lines and clinical biopsy specimens, in which the cytoplasmic p62 condensate formation positively correlated with EGFR-TKI resistance. Domain mapping demonstrated that the PB1 and UBA domains of p62 were critical for promoting phase separation and reducing sensitivity to EGFR-TKI treatment, whereas S403 phosphorylation promoted p62 condensation and EGFR-TKI resistance. Further xenograft studies validated that reduction of p62 condensation restores EGFR-TKI sensitivity. Kinase enrichment and interaction assays identified TBK1 as an upstream regulator of p62 S403 phosphorylation to promote p62 condensation after pharmacological inhibition of EGFR. Notably, among the five compounds identified from a drug library screen that both disrupted p62 condensate formation and inhibited the viability of resistant cells, the highly selective TBK1 inhibitor GSK8612 stood out. GSK8612 inhibited p62 S403 phosphorylation and consequently, at subcytotoxic doses, synergized with EGFR-TKIs to suppress the viability of resistant cells and tumor growth in the xenograft mouse model. These findings propose TBK1-p62 axis links p62 condensate homeostasis to EGFR-TKI resistance as an underlying mechanism of action and an emerging strategy to resensitize EGFR-TKI treatment in resistant lung cancer.